Recurrent Glioblastoma Clinical Trials in Boston, Massachusetts

5 studies are recruiting for recurrent glioblastoma in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. CARv3-TEAM-E T Cells in Glioblastoma

   The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital Cancer Center, Boston, Massachusetts

   Run by

   Marcela V. Maus, M.D.,Ph.D.

   See if you can join NCT05660369 on ClinicalTrials.gov

2. CUE-102 in Recurrent Glioblastoma

   The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of CUE-102 for participants with Recurrent Glioblastoma (GBM). The name of the study drug involved in this study is: -CUE-102 (a type of fusion protein)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   2 in total

   Run by

   David Reardon, MD

   See if you can join NCT06917885 on ClinicalTrials.gov

3. A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

   This research study is studying troriluzole as a possible treatment for recurrent glioblastoma. The name of the study drug involved in this research study is: -Troriluzole (a tripeptide prodrug of riluzole)

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   3 in total

   Run by

   Ugonma Chukwueke

   See if you can join NCT06552260 on ClinicalTrials.gov

4. The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

   Previous evidence has indicated that resection for recurrent glioblastoma might benefit the prognosis of these patients in terms of overall survival. However, the demonstrated safety profile of this approach is contradictory in the literature and the specific benefits in distinct clinical and molec…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   8 in total

   Run by

   Jasper Gerritsen

   See if you can join NCT06283927 on ClinicalTrials.gov

5. The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma

   Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site. To pursue maximal resection in a safe manner, mapping methods have been developed to test for motor and language function during the operation. Previous ev…

   Stage

   Not phased

   Ages

   Up to 90

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   8 in total

   Run by

   Erasmus Medical Center

   See if you can join NCT06273176 on ClinicalTrials.gov